Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing
However, both primary and acquired resistance frequently emerge through diverse genetic, epigenetic, and signaling alterations (Fig
MM: Writing review & editing, Funding acquisition, Validation
The lawful basis here is patient-specific 503A personalization for a documented clinical need, confirmed by the February 21, 2025 shortage end and the April 1, 2026 clarification that B12 add-ons alone do not automatically qualify a script
Most patients complete an initial protocol of 36 months
We recently demonstrated that GSH has a positive relationship with 25(OH)vitamin D 3 (25(OH)VD 3 ) in the blood of type 2 diabetic and obese subjects 6,7,8,9